CCA
DCPH

Catalyst Capital Advisors’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Catalyst Capital Advisors’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-305
Closed -$6K – 507
2017
Q3 		$6K Buy
+305
New +$5.59K ﹤0.01% 395

Other funds holding DCPH

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Catalyst Capital Advisors's DCPH Position: Q4 2017 in Review

Catalyst Capital Advisors sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q4 2017, closing a stake of 305 shares — an estimated $6K sold.

Catalyst Capital Advisors first reported a position in DCPH in Q3 2017 and held it in 1 quarter. The position peaked at $6K in Q3 2017. 59 funds tracked by Wall St. Rank hold DCPH as of Q4 2017.

  • Catalyst Capital Advisors reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Catalyst Capital Advisors sold 305 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q4 2017, an estimated $6K.
  • Catalyst Capital Advisors first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Catalyst Capital Advisors's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $6K in Q3 2017.
  • 59 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q4 2017.

Based on Catalyst Capital Advisors's 13F filing for Q4 2017, filed 8 Feb 2018.